Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

Guest Editorial

George Weiner: Cancer centers are special, as are site visits in CCSG review

Regulatory News

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

Clinical Trials & Tribulations

Working with cancer: Rethinking long-term health for working-age adult cancer survivors

Rewriting the rules of cancer treatment one nanobody at a time

Cancer Policy

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Bhattacharya cancels NIH all-hands meeting

NIH to update policies and practices, halting subawards to foreign entities

Women’s Health Initiative funding officially restored

AACR calls on Congress to reject Trump’s FY2026 budget request for NIH

PanCAN’s Julie Fleshman’s letter urges Congress to reject cuts to NIH

Clinical Roundup

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

Zinc-transporting protein contributes to aggressive growth of brain tumor, study shows

Dxcover presents first real-world evidence that increased tumor size is associated with higher mortality in brain cancer

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

In The Clinic

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Free

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

Latest Issue

Read the latest issue

DOWNLOAD THE PDF

NEWS ALERTS

Stay up to date on the latest news in oncology by joining our mailing list.

UPCOMING EVENTS

May 2025

2025 AAADV Workshop

23rd Cancer Center Summit: Accelerating Innovation in Oncology through AI

2025 ASCO Annual Meeting

View All Events

Conversations with The Cancer Letter

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Contributors

Betty Ferrell, PhD, MSN, CHPN

Advancing quality of life in oncology: A journey of compassion and innovation

W. Kimryn Rathmell, MD, PhD, MMHC

In her own words: Rathmell reflects on her priorities and values—and encourages everyone to do the same

Suresh S. Ramalingam, MD

Ci4CC’s 23rd Cancer Center Summit to focus on accelerating oncology innovation through AI

Mustafa Raoof, MD

Advancing peritoneal oncology: Innovations in surgical strategies and research

Trending Stories

NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science
Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit
Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
Did Vinay Prasad need to mention the Nazis to make a point on the U.S. pandemic response?
Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies
Prasad: FDA has confused merely approving drugs with making the world a better place

Recent Issues

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

George Weiner: Cancer centers are special, as are site visits in CCSG review

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

Working with cancer: Rethinking long-term health for working-age adult cancer survivors

Rewriting the rules of cancer treatment one nanobody at a time

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Bhattacharya cancels NIH all-hands meeting

NIH to update policies and practices, halting subawards to foreign entities

Women’s Health Initiative funding officially restored

AACR calls on Congress to reject Trump’s FY2026 budget request for NIH

PanCAN’s Julie Fleshman’s letter urges Congress to reject cuts to NIH

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Durvalumab regimen demonstrates improvement in DFS for high-risk NMBIC in phase III trial

Zinc-transporting protein contributes to aggressive growth of brain tumor, study shows

Dxcover presents first real-world evidence that increased tumor size is associated with higher mortality in brain cancer

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Betty Ferrell, PhD, MSN, CHPN

W. Kimryn Rathmell, MD, PhD, MMHC

Suresh S. Ramalingam, MD

Mustafa Raoof, MD

Never miss an issue!

Login

Trump administration is removing the mainstays of NCI and the federal government’s cancer programPeer review, registries, and evidence-based patient information take a big hit

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising recordCurrent record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Never miss an issue!

Login

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed